Intravitreal Antibiotics

Phase 3Small molecule

NNational Eye Institute (NEI)

Intravitreal Antibiotics is one of 5 small molecule programs targeting Endophthalmitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndophthalmitisActive, not recruiting

EndophthalmitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Endophthalmitis

#DrugCompanyPhaseTrials

Avelox

Bayer

Approved

5 2

Cipro

Bayer

Phase 2

1 3

Intravitreal Antibiotics

NNational Eye Institute (NEI)

Phase 3

1 4

Levaquin

WWim Janssens

Preclinical

1 5

Ceftin

PPhiladelphia Eye Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endophthalmitis1 trial

Endophthalmitis Vitrectomy Study (EVS)

Completed·NNational Eye Institute (NEI)·Phase 3·NCT00000130

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravitreal Antibiotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravitreal Antibiotics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravitreal Antibiotics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Eye Institute (NEI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Eye Institute (NEI)

Intravitreal Antibiotics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endophthalmitis1 trial

References

Drug Info

Quick Facts

Related News